Pleural Effusion and Pleural Disease

Pleural disease encompasses a range of conditions affecting the pleural space — the thin cavity between the two layers of membrane that surround each lung. Pleural effusion, the abnormal accumulation of fluid in this space, is among the most common pleural disorders encountered in clinical pulmonology, affecting an estimated 1.5 million people in the United States each year (American Thoracic Society). This page covers the definition and classification of pleural effusion and related pleural diseases, the underlying mechanisms, the clinical settings in which these conditions arise, and the diagnostic and management decision points that guide care. For a broader orientation to pulmonary medicine, the Pulmonary Authority home page provides an overview of the discipline.

Definition and scope

The pleural space normally contains only 10 to 20 milliliters of fluid, which serves as lubrication between the visceral pleura (covering the lung surface) and the parietal pleura (lining the chest wall and diaphragm). Pleural effusion is defined as a pathological excess of fluid in this space. The National Library of Medicine's MedlinePlus resource classifies pleural effusion broadly as either transudative or exudative, a distinction that carries direct diagnostic and management implications.

Beyond effusion, the category of pleural disease also includes:

Each subtype has distinct etiological profiles, imaging appearances, and treatment pathways. Physicians working in occupational and environmental medicine must also consider pleural plaques and mesothelioma, conditions regulated under standards administered by the Occupational Safety and Health Administration (OSHA) and tracked by the National Institute for Occupational Safety and Health (NIOSH). The regulatory context for pulmonary conditions page details relevant federal frameworks.

How it works

Fluid enters and exits the pleural space through hydrostatic and oncotic pressure gradients across the capillary walls of both pleural layers, supplemented by lymphatic drainage. The Light's Criteria, published by Richard Light and widely adopted in clinical practice, provide the foundational biochemical framework for classifying effusions:

  1. Exudative effusions result when pleural membranes become inflamed, infected, or involved by malignancy, disrupting capillary permeability and allowing protein-rich fluid to accumulate. An effusion is classified as exudative if pleural fluid protein divided by serum protein exceeds 0.5, pleural fluid LDH divided by serum LDH exceeds 0.6, or pleural fluid LDH exceeds two-thirds the upper limit of normal serum LDH (Light RW, Mayo Clinic Proceedings, 1972).

  2. Transudative effusions arise from systemic pressure imbalances — most commonly congestive heart failure, hepatic cirrhosis, or nephrotic syndrome — rather than local pleural pathology. These effusions do not meet Light's criteria thresholds.

Fluid accumulation reaching approximately 300 milliliters becomes detectable on upright chest radiograph as blunting of the costophrenic angle. Larger effusions compress adjacent lung parenchyma, reducing functional residual capacity and causing ventilation-perfusion mismatch, which manifests clinically as dyspnea and reduced oxygen saturation. A detailed discussion of lung mechanics is available at how the lungs work.

Empyema develops through three recognized stages: exudative (free-flowing infected fluid), fibropurulent (loculation and fibrin deposition), and organizing (thick fibrous peel restricting lung re-expansion). The American Thoracic Society and the Infectious Diseases Society of America (IDSA) have published joint guidelines addressing management of each stage.

Common scenarios

Pleural effusion appears across a wide range of clinical contexts. The four most frequently encountered etiological categories in US inpatient settings are:

  1. Congestive heart failure — accounts for approximately 500,000 pleural effusion diagnoses annually in the United States, typically producing bilateral transudative effusions (NIH National Heart, Lung, and Blood Institute)
  2. Pneumonia-associated (parapneumonic) effusion — exudative, ranging from uncomplicated reactive effusion to frank empyema; Streptococcus pneumoniae is among the most common causative organisms
  3. Malignancy — lung cancer, breast cancer, and lymphoma are the three most common malignancies producing pleural effusions; exudative cytology-positive fluid confirms pleural involvement
  4. Pulmonary embolism — produces small unilateral exudative effusions in roughly 30 percent of cases (NHLBI Pulmonary Embolism overview)

Less common but clinically important causes include tuberculosis (particularly in immunocompromised individuals), rheumatoid arthritis and other connective tissue diseases, post-cardiac injury syndrome, and drug-induced pleuritis. Occupational exposures to asbestos produce pleural plaques and, in higher cumulative dose exposures, malignant mesothelioma — a disease with a latency period commonly exceeding 30 years from first exposure.

Symptomatic presentation varies by fluid volume and acuity. Patients with small effusions may be asymptomatic, while larger collections produce pleuritic chest pain, dyspnea on exertion, and, in the setting of tension hemothorax or rapidly expanding malignant effusion, hemodynamic compromise.

Decision boundaries

Management decisions hinge on answering three sequential questions: whether to sample the fluid, what the fluid analysis reveals, and whether drainage is required or sufficient.

Diagnostic threshold for thoracentesis: The British Thoracic Society (BTS) guidelines recommend thoracentesis for all new unilateral effusions of unknown etiology and for bilateral effusions that do not resolve with treatment of the suspected systemic cause within 72 hours. Ultrasound-guided thoracentesis is the procedural standard, reducing pneumothorax risk to below 1 percent compared with landmark-guided approaches (BTS Pleural Disease Guideline 2010, updated recommendations).

Transudative vs. exudative differentiation: When fluid analysis confirms a transudate, the underlying systemic condition (heart failure, cirrhosis, nephrotic syndrome) drives further management. When an exudate is confirmed, additional fluid studies — cytology, culture, pH, glucose, adenosine deaminase — narrow the differential.

Drainage indications:

  1. Symptomatic large effusion — therapeutic thoracentesis removes up to 1,500 milliliters per procedure to relieve dyspnea and restore lung volume
  2. Empyema or complicated parapneumonic effusion with pH below 7.2 — requires chest tube drainage; IDSA guidelines support early intervention to prevent progression to the organizing stage
  3. Recurrent malignant effusion — candidates for indwelling pleural catheter (IPC) placement or chemical pleurodesis using agents such as talc, which achieves successful pleurodesis in approximately 60 to 90 percent of cases depending on technique and underlying disease (American Thoracic Society)
  4. Hemothorax — requires drainage to prevent fibrothorax; surgical decortication is indicated when retained clotted hemothorax exceeds 200 to 300 milliliters or fails to resolve with tube drainage

Pneumothorax management boundaries follow a separate decision tree based on lung collapse percentage, patient symptoms, and whether the pneumothorax is primary spontaneous (no underlying disease), secondary spontaneous (underlying lung disease such as COPD), or traumatic. BTS and American College of Chest Physicians (ACCP) guidelines both distinguish conservative observation from needle aspiration or chest tube insertion based on collapse size thresholds, typically set at 2 to 3 centimeters on chest radiograph.

Pleural disease with occupational etiology falls under OSHA's asbestos standard (29 CFR 1910.1001 for general industry), which mandates medical surveillance for workers with documented exposure histories. NIOSH criteria documents provide exposure-response data used in these regulatory frameworks.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)